R&D Changing how the world finds new medicines: Physics modellin... Finding treatments for diseases afflicting humanity often proceeds at a crawl, leaving many serious medical needs unmet.
Digital JPM2026: Broadening AI drug discovery to include the lab, wi... Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.
News J&J bets on Isomorphic for AI-powered drug hunt Isomorphic Labs has added Johnson & Johnson to the roster of pharma companies tapping into its AI-based drug discovery engine.
News EMA and FDA agree 'principles' for AI in drug development The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development.
News Now Iktos teams up with Pierre Fabre in oncology As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos
News Servier signs €1bn-plus AI pact with Iktos In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
